OQROGet OQRO Pro
Insider trade

AbbVie (ABBV)Officer sold ~$970K

Timothy J. Richmond, Officer at AbbVie, sold ~$970K of AbbVie shares.

~$970K
Approx. value · 4,781 sh @ $202.93
46K
Holds after · shares reported
Traded
Feb 26, 2025
Filed
Feb 28, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 6, 2024CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  2. Jan 15, 2025Congress · 1 personMembers of Congress: 2 purchases
  3. Feb 7, 2025FDAFDA drug approval: Emblaveo
  4. Feb 20, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  5. Feb 24, 2025CongressDisclosed purchase of ABBV — reported range $50,001 - $100,000
  6. Feb 25, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  7. Feb 26, 2025 · this disclosureInsiderOfficer sold ~$970K of ABBV shares in the open market

What came next

  1. Feb 26, 2025Insider · 2 peopleInsiders: 7 sales (~$9.0M)
  2. Feb 28, 2025Insider · 2 peopleInsiders: 4 sales (~$21.0M)
  3. Mar 3, 2025Insider · 3 peopleInsiders: 5 sales (~$9.6M)
  4. Mar 14, 2025InsiderCFO sold ~$3.75M of ABBV shares in the open market
  5. Mar 17, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  6. Mar 31, 2025Insider · 1 personInsiders: 2 sales (~$12.4M)
  7. Apr 1, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  8. Apr 3, 2025Congress · 2 peopleMembers of Congress: 1 purchase, 1 sale
  9. Apr 7, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  10. Apr 8, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  11. Apr 17, 2025Congress · 2 peopleMembers of Congress: 2 sales
  12. Apr 28, 2025FDAFDA drug approval: Rinvoq
  13. May 5, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  14. May 14, 2025FDAFDA drug approval: Emrelis
  15. May 15, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  16. May 22, 2025FDAFDA drug approval: Lupron Depot-Ped Kit
  17. May 22, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  18. Jun 10, 2025FDAFDA drug approval: Mavyret
  19. Jun 10, 2025FDAFDA drug approval: Mavyret
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for AbbVie

For AbbVie, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 130 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

Other recent filings by Timothy J. Richmond, EVP, CHIEF HR OFFICER

The full history of Timothy J. Richmond, EVP, CHIEF HR OFFICER is on the profile page.

How this filing works

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data